Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,917 signal articles · 64 in last 24h · 135,654 total before filter · latest 17m ago
64last 24h
1097last 7d
178● bullish (7d)
141● bearish (7d)
209publishers
AllMacro302Earnings359M&A77Regulatory25Product11Analyst14
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Spire Global Q2 Earnings Call Highlights
MarketBeat23d agoneutral
Spire Global Q2 Earnings Call Highlights

Spire Global (NYSE:SPIR) reported second-quarter revenue of $18 million and reaffirmed its 2026 revenue outlook of $75 million to $85 million, as the satellite-data company cited growing government weather, radio frequency geolocation and international defense opportunities. Chief Executive Officer

Nebius stock quietly defies its own history after earnings
TheStreet23d agoneutral
Nebius stock quietly defies its own history after earnings

Nebius Group (NBIS) has trained its investors to brace for disappointment on days when the headlines look strong. In May, the company reported blowout first-quarter results, only to watch its stock fall almost 9% the following Monday. That pattern is exactly why the reaction stood out on Wednesday, ...

Nano Nuclear Energy Q3 Earnings Call Highlights
MarketBeat23d agoneutral
Nano Nuclear Energy Q3 Earnings Call Highlights

Nano Nuclear Energy (NASDAQ:NNE) said its third-quarter progress centered on advancing the licensing and engineering of its Kronos microreactor, expanding its nuclear fuel-cycle capabilities through acquisitions, and pursuing potential commercial deployments for data centers, industrial users and go

Inovio Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat23d agoneutral
Inovio Pharmaceuticals Q2 Earnings Call Highlights

Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues prepara